2017 Annual Meeting

Endocrine Pathology Society

March 4 2017, 7:00pm to 10:00pm


Endocrine Pathology Society

The value and pitfalls of Ki67 in the diagnosis of endocrine neoplasms

Saturday, March 4, 2017
7:00 PM 10:00 PM
CC Hemisfair 2


Session Credits: 3 CME and 3 SAMs


Moderators: Hironobu Sasano, MD, PhD, Tohoku University School of Medicine, Sendai, Japan
Ricardo V. Lloyd, MD, PhD, The University of Wisconsin, Madison, WI

Course Description:
Ki67 labeling index (LI) has been established as the reliable method of demonstrating the proliferative activity of tumor cells and is replacing classical mitotic index in potential classification, prediction of clinical outcome and therapeutic response to adjuvant or neoadjuvant therapy and others. Therefore, the exact value of Ki67 LI has been frequently asked by clinical oncologists managing the patients with cancer patients. In particular, among endocrine neoplasms, Ki67 LI plays indispensable roles in surgical pathology diagnosis of neuroendocrine neoplasms in pancreas, GI tract and lung, pituitary tumors and adrenal neoplasms, especially adrenocortical carcinoma. However, it is also true that the methodology of obtaining Ki67 LI has not been standardized especially in where to be evaluated, hot spots versus average and how to be counted, eye ball versus computer assisted image analysis. Therefore, in this companion symposium, the value and pitfalls of Ki67 labeling index will be summarized in lung, pancreas and GI tract neuroendocrine neoplasms, pituitary tumors and adrenal neoplasms.

Upon completion of this educational activity, participants should be able to:

  • Describe the importance and limitations of Ki67 labeling index in endocrine tumors including the value of threshold in discerning malignancy in individual endocrine tumors, possible overlap between benign and malignant endocrine tumors, its value as surrogate markers for adjuvant and neoadjuvant therapy in specific endocrine tumors
  • Identify the threshhold of Ki67 labeling index for discerning malignancy in endocrine tumors according to WHO classification and other guidelines. The proposed thresh-hold of Ki67 LI in selecting specific medical therapy in endocrine neoplasms to communicate with clinical oncologists or endocrinologists. The importance of standardization of Ki67 LI as well as its limitations.
  • Incorporate the absolute Ki67 labeling index number in surgical pathology report of endocrine neoplasms including the methodology of immunostaining and scoring


7:00 PM

Introduction: Ki67; Average Versus Hot Spots; Eye Ball Versus Image Analysis
Hironobu Sasano, MD, PhD, Tohoku University School of Medicine, Sendai, Japan

7:15 PM

Ki67 in Pancreatic NEN or Neuroendocrine Neoplasm According to WHO 2017
Günter Klöppel, MD, PhD, Consultation Center for Pancreatic and Endocrine Tumors, Mnchen, Germany

7:45 PM

Ki67 in Pituitary Tumors: What Information Could We Obtain?
Robert Yoshiyuki Osamura, MD, PhD, International University of Health and Welfare Mita Hospital, Tokyo, Japan

8:00 PM

The Role of Ki67 in Pulmonary Neuroendocrine Tumors
William Travis, MD, Memorial Sloan Kettering Cancer Center, New York, NY

8:30 PM

The Value and Pitfalls of Ki67 Labeling Index in Gastrointestinal NEN or Neuroendocrine Neoplasm
Stefano La Rosa, MD, PhD, Institut Universitaire de Pathologie, Lausanne, Switzerland

8:55 PM

Advantages and Limitations of Assessing Proliferation in Adrenal Tumors for Diagnosis and Prognosis
Thomas Giordano, MD, PhD, University of Michigan, Ann Arbor, MI

9:20 PM

Summary of Talks
Ricardo V. Lloyd, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, WI


view more